SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) occupy a pivotal role in the management of Type 2 diabetes due to their unique glucose-lowering mechanism and multiple clinical benefits.